- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Roche promotional materials for Vabysmo (faricimab) were ruled misleading where “first and only” wording and “may confer additional benefits” implied special clinical…
PMCPA found Roche breached Clause 5.5 because a patient summary of an AMD audit report did not disclose Roche’s funding within the…
A third-party publisher sent an EU-focused Pluvicto promo email to UK HCPs after a “Europe” targeting error. Panel found disguised promotion, unclear…
A Jardiance case-study slide deck remained accessible via a live URL long after retirement, wasn’t recertified within 2 years, and the PI…
Jazz funded a patient organisation’s health information project, but Jazz’s involvement wasn’t clearly acknowledged from the outset on the website and wasn’t…
A UK health professional complained about Janssen’s HCP website. The Panel found some prescribing information was out-of-date, one graph exaggerated differences, and…
A GP complained that he continued to receive promotional emails after opting out. A third-party agency failed to remove his details, and…
A Financial Times article triggered a Director complaint about Lilly’s 40over40 ED campaign. TV ad was not in breach, but website/leaflet treatment…
AstraZeneca challenged Trinity-Chiesi’s Fostair cost comparison chart as incomplete and misleading. The Panel found the chart acceptable in context and ruled no…
A pharmacist challenged claims that Versatis was comparable to pregabalin (and possibly gabapentin) and had fewer side-effects/interactions. The Panel found interim data…
A GP received an unsolicited promotional email about MacroBid via an agency. The Panel and Appeal Board found no evidence of prior,…
AstraZeneca self-reported an uncertified promotional email about Crestor sent to a dispensing practice. The email lacked prescribing information and included misleading, exaggerated…
Two anonymous hospital HCPs alleged an AstraZeneca rep initiated discussion of unpublished/out-of-licence JUPITER (Crestor) data. Panel had concerns about internal briefings but…
A Lipitor mailer compared LDL-C lowering across statins but then presented a table implying only Lipitor/rosuvastatin/ezetimibe combos had outcomes trials. Panel ruled…
GSK and Roche withdrew Bonviva ‘Building Bones’ materials after an undertaking, but Pulse republished the old ad. Panel ruled breach of Clause…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.